Shares of Verastem Inc. (VSTM) jumped 50.3% to $5.77 ahead of the market open on Wednesday, Sept. 6, after the Boston firm announced positive top-line results from its Phase 3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Also on Wednesday, the company said it has broadened its duvelisib development program to include targeting the treatment of patients with peripheral T-cell lymphoma. The U.S. Food & Drug Administration has given duvelisib fast track designation for the treatment of patients with PTCL that have received at least one prior therapy.
In addition, Verastem said it has tapped Brian Stuglik, an Eli Lilly & Co. (LLY) alum who later founded Proventus Health Solutions LLC, as a board member.
Meanwhile, Sarepta Therapeutics Inc. (SRPT) shares rose nearly 14% to $46.80 after the Cambridge, Mass.-based firm unveiled muscle biopsy results from its Phase 1/2 study in Europe of golodirsen in boys with confirmed deletions of the DMD gene amenable to skipping exon 53.
Among the other biotech movers was Merrimack Pharmaceuticals Inc. (MACK) , up nearly 16% to $14.49.
More of What's Trending on TheStreet: